Feilong Shares Forecasts Q1–Q3 Net Profit Down 59.2%–66.87%; New Asia Technology Plans Restructuring and Trading Halt

CLS··CNUSEU·Read original
3▲2 ▼1Impact / 5
Summary · why it matters

Feilong Shares announced that net profit attributable to shareholders for the first three quarters of 2026 is expected to be between 95 million yuan and 117 million yuan, down 59.20% to 66.87% year on year, mainly due to the combined impact of multiple phased factors including intensifying industry competition, rising raw material prices, exchange rate fluctuations, and new businesses still in the incubation period. At this stage, revenue from non-automotive businesses accounts for a relatively low proportion of overall revenue. New Asia Technology is planning to acquire a controlling stake in Shanghai Qiyuan Gas Development Co., Ltd. through the issuance of shares and cash payment, and to raise supporting funds. The transaction is expected to constitute a major asset restructuring, and trading in the company's securities has been suspended since the market opened on October 8, 2026. Huahai Pharmaceutical expects net profit for the first three quarters of 2026 to be between 1.028 billion yuan and 1.103 billion yuan, up 170% to 190% year on year, mainly due to a significant increase in sales revenue from the active pharmaceutical ingredients business, expansion of products winning bids under centralized procurement in the domestic finished drug business, a turnaround to profitability in the US finished drug business, as well as gains from winning an arbitration and a reduction in research and development expenses. Asieris Pharmaceuticals has signed a conditional exclusive license agreement with Theramex, under which Theramex obtains exclusive rights to APL-1702 in European countries as well as Australia, New Zealand, and Turkey. The company will receive an upfront payment of 15 million US dollars, a near-term regulatory milestone payment of 11 million US dollars, as well as commercial milestone payments and tiered sales royalties, with the total transaction value exceeding 250 million US dollars. COSCO Shipping Holdings has completed its A-share repurchase, actually repurchasing 50.0175 million shares, accounting for 0.3276% of total share capital, with a repurchase amount of 755 million yuan and a repurchase price range of 13.69 yuan to 16.42 yuan per share. The company will cancel the repurchased shares on October 8.

Impact on assets 6

Others± Mixed · 6 stocks
Jiangsu Yahong Meditech Co. Ltd.
688176
▲ PositiveDemandrelevance

Asieris signs exclusive license agreement with Theramex for APL-1702 in Europe, Australia, New Zealand, and Turkey, receiving upfront and milestone payments.

Off-coverage companies 2

TheramexPrivate▲ Positive
Demandrelevance

Theramex obtains exclusive rights to APL-1702 in European countries, Australia, New Zealand, and Turkey under a license agreement with Asieris.

上海启元气体发展有限公司Private± Mixed
Capitalrelevance

New Asia Technology plans to acquire a controlling stake in Shanghai Qiyuan Gas Development via share issuance and cash, constituting a major asset restructuring.

© 2026 MarketIVNews